Shopping Cart
- Remove All
- Your shopping cart is currently empty
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $34 | In Stock | |
5 mg | $55 | In Stock | |
10 mg | $89 | In Stock | |
25 mg | $119 | In Stock | |
50 mg | $155 | In Stock | |
100 mg | $239 | In Stock | |
1 mL x 10 mM (in DMSO) | $71 | In Stock |
Description | CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM. |
Targets&IC50 | BTK:1.9 nM |
In vitro | Treatment with CGI1746 at a dose of 100 mg/kg, administered subcutaneously twice daily, resulted in a significant suppression (97%) of overall clinical arthritis symptoms. In a positive anti-collagen type II antibody-induced arthritis model, CGI1746 significantly reduced levels of TNFα, IL-1β, and IL-6, as well as MCP-1 and MIP-1α mRNA and protein. In mice and rats with arthritis, CGI1746 demonstrated superior efficacy compared to TNFα blockade, significantly lowering clinical scores while also reducing joint inflammation. |
In vivo | CGI1746 effectively inhibits the proliferation of CD27+IgG+ B cells isolated from the tonsils of four donors, with an average IC50 of 112 nM. It completely suppresses B cell proliferation induced by anti-IgM in both mice and humans, with IC50s of 134 nM and 42 nM, respectively, yet does not affect T cell proliferation induced by anti-CD3 and anti-CD28. In macrophages, CGI1746 eliminates the production of TNFα, IL-1β, and IL-6 triggered by FcγRIII. It also efficiently inhibits the production of TNFα and IL-1β in human monocytes stimulated by immobilized or soluble immune complexes, and to a lesser extent, reduces IL-6 production. CGI1746 shows high specificity and selectivity for Btk, being ~1,000 times more selective than for Tec and Src family kinases. |
Cell Research | CGI-1746 is dissolved in DMSO. 5×103?DU145 cells or 104?LNCaP cells per well, grown on 96 well plates for 24h, are treated with 1 to 30?μM BTK inhibitors. Cells are fixed after 72h with 2.5% formaldehyde, and stained with Hoechst 33342. Control cells are treated with DMSO. Cell images are acquired using an IN Cell Analyzer 2200 high content imaging system, with a 20X objective. At least 9 fields are imaged per single well of each experiment. Cell numbers are determined and statistics performed using IN Cell Investigator 3.4 high content image analysis software. Each experiment is replicated 3 times, and data are presented as mean±SD. Results are considered significant if p < 0.05. |
Molecular Weight | 579.69 |
Formula | C34H37N5O4 |
Cas No. | 910232-84-7 |
Smiles | CC1=C(C=CC=C1NC(=O)C2=CC=C(C(C)(C)C)C=C2)C=3N=C(NC4=CC=C(C(=O)N5CCOCC5)C=C4)C(=O)N(C)C3 |
Relative Density. | 1.22 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 95 mg/mL (163.9 mM) Ethanol: 33 mg/mL (57 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.